CSBR — Champions Oncology Share Price
Last trade - 00:00- $66.67m
- $63.16m
- $59.43m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 17.13 | ||
| Price to Tang. Book | 18.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.1 | ||
| EV to EBITDA | 180.46 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.02% | ||
| Return on Equity | -29.83% | ||
| Operating Margin | -1.68% | ||
Financial Summary
| Year End 30th Apr | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 49.11 | 53.87 | 50.16 | 56.94 | 59.42 | 65.26 | 70.81 | 7.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +64.04 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Its pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development. The Company operates in one segment pertaining to oncology services. Its research platform is a proprietary bank of Patient Derived Xenograft (PDX) models. Its PDX models are deployed into advanced vivo and ex vivo pharmacology platforms, providing an insight into therapeutic programs. The PDX bank is characterized at the molecular, phenotypic and pharmacological levels, which provides a differentiated layer of data for its oncology dataset.
Directors
- Joel Ackerman NEC (56)
- Ronnie Morris CEO (55)
- David Miller CFO (52)
- David Sidransky LED (55)
- Robert Brainin DRC (50)
- Philip Breitfeld IND (68)
- Daniel Mendelson IND (57)
- Scott Tobin IND (50)
- Last Annual
- April 30th, 2026
- Last Interim
- July 31st, 2026
- Incorporated
- June 4th, 1985
- Public Since
- November 30th, 1988
- No. of Shareholders
- 1,900
- No. of Employees
- 217
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 13,918,569
- Address
- One University Plaza,, Suite 307, HACKENSACK, 07601
- Web
- https://www.championsoncology.com
- Phone
- +1 2018088400
- Auditors
- EisnerAmper LLP
Latest News for CSBR
Upcoming Events for CSBR
Champions Oncology Inc Annual Shareholders Meeting
Q2 2027 Champions Oncology Inc Earnings Release
Q3 2027 Champions Oncology Inc Earnings Release
Similar to CSBR
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 01:54 UTC, shares in Champions Oncology are trading at $4.79. This share price information is delayed by 15 minutes.
Shares in Champions Oncology last closed at $4.79 and the price had moved by -27.2% over the past 365 days. In terms of relative price strength the Champions Oncology share price has underperformed the S&P500 Index by -37.68% over the past year.
The overall consensus recommendation for Champions Oncology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreChampions Oncology does not currently pay a dividend.
Champions Oncology does not currently pay a dividend.
Champions Oncology does not currently pay a dividend.
To buy shares in Champions Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $4.79, shares in Champions Oncology had a market capitalisation of $66.67m.
Here are the trading details for Champions Oncology:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CSBR
Based on an overall assessment of its quality, value and momentum Champions Oncology is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Champions Oncology is $12.00. That is 150.52% above the last closing price of $4.79.
Analysts covering Champions Oncology currently have a consensus Earnings Per Share (EPS) forecast of $0.10 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Champions Oncology. Over the past six months, its share price has underperformed the S&P500 Index by -27.14%.
As of the last closing price of $4.79, shares in Champions Oncology were trading -18.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Champions Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Champions Oncology's management team is headed by:
- Joel Ackerman - NEC
- Ronnie Morris - CEO
- David Miller - CFO
- David Sidransky - LED
- Robert Brainin - DRC
- Philip Breitfeld - IND
- Daniel Mendelson - IND
- Scott Tobin - IND